Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

Translational Oncology Research International

Status and phase

Completed

Phase 2

Conditions

Prostate Cancer

Treatments

Drug: Erlotinib + Bevacizumab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00203424

TORI GU-01

05-07-102 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.

Full description

This study explores the anti-tumor activity of adjuvant bevacizumab plus erlotinib in a select group of prostate cancer patients deemed at high risk for early relapse following radical prostatectomy.

Enrollment

23 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Karnofsky performance status of > 80
Patients must have localized, organ-confined prostate cancer documented by physical examination, CT scan, or bone scan, and must have undergone radical prostatectomy. Post RP must have documented node negative prostate cancer.
Pretreatment granulocyte count > 1500/mm3, hemoglobin > 9.0 g/dL, and platelet count > 100,000/mm3,
Normal PT and PTT
Serum creatinine < 2.0 mg/dL
Adequate hepatic function with a serum bilirubin < upper limit of normal (ULN), AST and ALT < 1.5x ULN, and alkaline phosphatase < 2.5x ULN.
High-risk prostate cancer defined as a pre-RP prostate specific antigen level > 15 ng/dL or a Gleason score of > 8 or Stage T3 disease or positive surgical margins
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for 3 months thereafter

Exclusion criteria

Evidence of small cell (neuroendocrine) tumor
Evidence of metastatic disease
Prior administration of immunotherapy, biological therapy, hormonal therapy or radiation therapy for prostate cancer
Active secondary malignancies (other than basal cell carcinoma of the skin)
Serious, nonhealing wound, ulcer, or bone fracture.
Clinically significant cardiovascular disease (e.g., blood pressure of >150/100 mmHg, myocardial infarction, or unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or clinically significant peripheral vascular disease. Patients with a history of myocardial infarction or stroke within the last 6 months will be excluded.
Presence of seizures not controlled with standard medical therapy
Active infection requiring parenteral antibiotics at the time of the first administration of study drugs
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0.
Current, recent (within the 4 weeks preceding Day 0), or planned participation in another experimental drug study
Inability to comply with the study visit and follow-up schedule or procedures
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
Urine protein:creatinine ration > 1.0 at screening
Evidence of bleeding diathesis or coagulopathy.
History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days prior to Day 0.
Presence of central nervous system or brain metastases